PravastatinThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10

482 records returned

Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The major initiation process of intracranial aneurysms is thought to involve endothelial dysfunction due to hemodynamic stress. Angiotensin II type 1 receptor blockers and statins improve vascular endothelium function. The effects of olmesartan and pravastatin were investigated on the development of experimental aneurysms in rats. Eighty-three rats underwent aneurysm induction. Seven groups of 10-14 rats were treated with low or high dose olmesartan, low or high dose pravastatin, low doses of olmesartan and pravastatin, hydralazine, or no drug (control) for 12weeks, when rats were sacrificed for vascular corrosion cast...
Source: Brain Research - January 26, 2010 Category: Neurology Authors: Kimura N, Shimizu H, Eldawoody H, Nakayama T, Saito A, Tominaga T, Takahashi A Tags: Brain Res Source Type: journals

Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Initiation of a fibrate or statin that inhibits CYP3A4 enzymes, including atorvastatin, was associated with an increased risk of hospitalization for gastrointestinal bleeding. Initiation of pravastatin, which is mainly excreted unchanged, was not associated with an increased risk. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - January 24, 2010 Category: Journals (General) Authors: Hedi Schelleman, Warren B. Bilker, Colleen M. Brensinger, Fei Wan, Yu-Xiao Yang, Sean Hennessy Tags: Clinical research studies Source Type: journals

Red Yeast Rice Comparable to Pravastatin for Statin-Intolerant PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Red-yeast-rice and pravastatin treatment arms both had low withdrawal rates and achieved comparable reductions in LDL-cholesterol levels, report researchers. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 22, 2010 Category: Consumer Health News Tags: Cardiology Source Type: news

Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions and implications: We demonstrated that the conserved positively charged amino acids Lys41 and Arg580 are pivotal to the transport activity of OATP1B3. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - January 22, 2010 Category: Drugs & Pharmacology Authors: H Glaeser, K Mandery, H Sticht, MF Fromm, J König Source Type: journals

Red yeast rice comparable to pravastatin for statin-intolerant patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Red-yeast-rice and pravastatin treatment arms both had low withdrawal rates and achieved comparable reductions in LDL-cholesterol levels, report researchers. For complete story visit theheart.org. (Source: theHeart.org)
Source: theHeart.org - January 21, 2010 Category: Cardiology Source Type: info

Endothelial Function Impairment in Chronic Venous Insufficiency: Effect of Some Cardiovascular Protectant AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In segments of human varicose veins, endothelial function was assessed by measuring relaxation induced by acetylcholine in noradrenaline-precontracted preparations. In addition, concentration-response curves to acetylcholine were obtained before and after incubation with the arterial endothelium protectant agents captopril, losartan, troglitazone, pravastatin, or simvastatin. The antivaricose agent escin was also tested. Mean acetylcholine-induced relaxation of varicose venous rings was about 13%, approximately one third of that reported for control saphenous veins. Concentration-response curves to acetylcholine were &lsqu...
Source: Angiology - January 21, 2010 Category: Cardiology Authors: Carrasco, O. F., Ranero, A., Hong, E., Vidrio, H. Tags: Articles Source Type: journals

Study Finds Red Yeast Rice Efficacy Comparable to StatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The alternative therapy red yeast rice performes comparably to the lipid-lowering drug pravastatin in reducing low-density lipoprotein cholesterol levels in patients who had previously had to discontinue statin therapy because of muscle pain, according to a study in the Jan. 15 issue of the American Journal of Cardiology. (Source: Modern Medicine)
Source: Modern Medicine - January 21, 2010 Category: Journals (General) Source Type: info

Variation in the CBP gene involved in epigenetic control associates with cognitive function.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Research into the pathologic mechanisms of neurodegenerative diseases has revealed that CREB binding protein (CBP) plays an important role in cognitive dysfunction. Loss of one copy of this gene leads to a syndrome with severe cognitive dysfunction. We investigated the association between four common variants in the CBP gene and cognitive function in 5804 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Baseline associations between genetic variation and cognitive function were assessed with linear regression. Longitudinal associations were assessed with linear mixed models. All an...
Source: Neurobiology of Aging - January 21, 2010 Category: Geriatrics Authors: Trompet S, Craen AJ, Jukema JW, Pons D, Slagboom PE, Kremer D, Bollen EL, Westendorp RG Tags: Neurobiol Aging Source Type: journals

Beneficial microvascular and anti-inflammatory effects of pravastatin during sepsis involve nitric oxide synthase IIIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Pravastatin improved NOS III-mediated vessel relaxation and exerted anti-inflammatory effects within the microcirculation after LPS administration in rats. Pravastatin therefore appears to have beneficial effects during sepsis, as a result of increased microvascular expression and function of NOS III. (Source: British Journal of Anaesthesia)
Source: British Journal of Anaesthesia - January 19, 2010 Category: Anesthesiology Authors: McGown, C. C., Brown, N. J., Hellewell, P. G., Reilly, C. S., Brookes, Z. L. S. Tags: Critical Care Source Type: journals

Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review evaluated the effectiveness statins in preventing cerebral vasospasm in patients who have had aneurysmal subarachnoid haemorrhage (SAH). The evidence suggested that statins may be promising, but the authors' conclusions appear over-optimistic given the limited evidence available. [Two studies used 80 mg simvastatin daily. One study used 40 mg pravastatin daily.] CRD Commentary: This review addressed a clear question supported by appropriate inclusion criteria. A number of relevant electronic databases were searched without language restrict...
Source: NeLM - Cerebrovascular Disorders - January 18, 2010 Category: Neurology Source Type: organizations

Myelin Basic Protein Priming Reduces the Expression of Foxp3 in T Cells via Nitric Oxide.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Regulatory T cells (Tregs) play a vital role in autoimmune disorders. Among several markers, forkhead box p3 (Foxp3) is the most specific with regard to Treg activity. Therefore, understanding mechanisms that regulate Foxp3 expression is a critical step for unraveling the complicacy of autoimmune pathophysiology. The present study was undertaken to investigate the crosstalk between NO and Tregs. Interestingly, after myelin basic protein (MBP) priming, the expression of Foxp3 decreased in MBP-primed T cells. However, blocking NO either by inhibiting inducible NO synthase with l-N(6)-(1-iminoethyl)-lysine hydrochloride o...
Source: Journal of Immunology - January 18, 2010 Category: Allergy & Immunology Authors: Brahmachari S, Pahan K Tags: J Immunol Source Type: journals

Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Epidemiologic studies have shown that a low level of high-density lipoprotein (HDL) cholesterol is a risk factor for cardiovascular diseases. The purpose of this study was to determine the contribution of isolated low HDL cholesterol to endothelial function. Thirty-nine subjects with low HDL cholesterol who had no other cardiovascular risk factors were selected from the 5,417 participants from our population. We evaluated flow-mediated vasodilation (FMD) before and after 4 wk of treatment with the HMG-CoA reductase inhibitor pravastatin in 29 of the 39 subjects with isolated low HDL cholesterol. FMD was lower in the low-HD...
Source: AJP: Endocrinology and Metabolism - January 15, 2010 Category: Endocrinology Authors: Higashi, Y., Matsuoka, H., Umei, H., Sugano, R., Fujii, Y., Soga, J., Kihara, Y., Chayama, K., Imaizumi, T. Tags: Articles Source Type: journals

ReplyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
First, we express our deep appreciation for the sincere criticism by Dr. Kaneda and colleagues of our paper (). However, we have a few concerns regarding their arguments. The REVERSAL (REVERSing Atherosclerosis with Aggressive Lipid Lowering) study () examined patients with stable coronary artery disease who could undergo an elective cardiac catheterization, whereas the PROVE-IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) () and our JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) study examined patients with ac...
Source: Journal of the American College of Cardiology - January 14, 2010 Category: Cardiology Authors: Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki Tags: Letters to the Editor Source Type: journals

Low-dosage statins reduce choroidal damage in hypercholesterolemic rabbitsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Treatment with a low dosage of fluvastatin sodium or pravastatin sodium reduced the lipid build-up as well as the macrophages in the choroid and restored the vascular lumens of choroidal vessels independently of the cholesterol effect. The normal ultrastructural features of choroidal EC and VSMC in statin-treated animals suggest that the endothelial function is preserved and the ischaemia reduced. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - January 8, 2010 Category: Opthalmology Authors: Blanca Rojas, Ana I. Ramírez, Juan J. Salazar, Rosa de Hoz, Alma Redondo, Rafaela Raposo, Teresa Mendez, Teresa Tejerina, Alberto Triviño, Jose M. Ramírez Source Type: journals

Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study investigated the protective effects of pravastatin against cisplatin-induced nephrotoxicity and the possible mechanisms in mice. Pravastatin showed significant protection as evidenced by the decrease of elevated serum creatinine (CRE) and blood urea nitrogen (BUN), and improvement of histopathological injury induced by cisplatin. The formation of kidney malondialdehyde (MDA) with a concomitant reduction of reduced glutathione (GSH) were inhibited by pravastatin, while the activities of kidney superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-px) were increased. The over expressions of ki...
Source: Experimental and Toxicologic Pathology - January 7, 2010 Category: Pathology Authors: An Y, Xin H, Yan W, Zhou X Tags: Exp Toxicol Pathol Source Type: journals

Coronary Heart Disease in Moderately Hypercholesterolemic, Hypertensive Black and Non-Black Patients Randomized to Pravastatin Versus Usual CareEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Coronary heart disease endpoints are examined in relation to race and Pravastatin use. Does Pravastatin prevent CHD in blacks? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2010 Category: Consumer Health News Tags: Cardiology Source Type: news

Relation of Change in Apolipoprotein B/Apolipoprotein A-I Ratio to Coronary Plaque Regression After Pravastatin Treatment in Patients With Coronary Artery DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Some investigations have looked into the ability of measurements of apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio to predict cardiovascular events. We hypothesized that a decrease in the apoB/apoA-1 ratio by statin therapy would act on suppression of coronary plaque progression. A 6-month prospective study was conducted of 64 patients with coronary artery disease treated with pravastatin. The plaque volume, assessed by volumetric intravascular ultrasonography, had decreased significantly by 12.6% (p (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 5, 2010 Category: Cardiology Authors: Shigemasa Tani, Ken Nagao, Takeo Anazawa, Hirofumi Kawamata, Shingo Furuya, Hiroshi Takahashi, Kiyoshi Iida, Michiaki Matsumoto, Takehiko Washio, Narimichi Kumabe, Atsushi Hirayama Tags: Coronary Artery Disease Source Type: journals

Pravastatin Protects Against Heart Disease in BlacksEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The cholesterol-lowering drug pravastatin prevents coronary heart disease in blacks, according to trial results published in the December American Heart Journal. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2010 Category: Consumer Health News Tags: Cardiology Source Type: news

The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The combination of diabetes and hyperlipidemia promotes the development of atherosclerosis. Therefore, it is important for diabetic patients to control blood fat. 3-Hydroxy-3-methylglutaryl enzyme A (HMG-CoA) reductase inhibitors (statins), like pravastatin, are frequently administered to diabetic patients for this purpose. Although the alterations of metabolic enzymes and transporters in the diabetic liver maybe change the disposition of pravastatin, the effect has not been fully investigated. In the present study, we investigated the disposition of pravastatin and the mRNA expression of transporters in the liver. Pra...
Source: Biological and Pharmaceutical Bulletin - January 1, 2010 Category: Drugs & Pharmacology Authors: Hasegawa Y, Kishimoto S, Shibatani N, Inotsume N, Takeuchi Y, Fukushima S Tags: Biol Pharm Bull Source Type: journals

In vitro antioxidant activity of pravastatin provides vascular protection.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, this study can contribute to elucidate the mechanism responsible for the antioxidant activity of pravastatin, and describes relationship between a scavenger effect of pravastatin and the improvement of vascular reactivity. PMID: 20044990 [PubMed - as supplied by publisher] (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - December 29, 2009 Category: Drugs & Pharmacology Authors: Kassan M, Montero MJ, Sevilla MA Tags: Eur J Pharmacol Source Type: journals

Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LDL-apheresis (LDLa) efficacy in the treatment of symptomatic HyperLp(a)lipoproteinemia -HyperLp(a)- has been studied in a multicentre trial. After 3.1+/-2.7 years of weekly and biweekly treatment, the data from 19 patients (males:12; females:7; aged 53.8+/-9.3 years; mean body mass index: 24.6+/-2.3 Kg/m(2)) were evaluated. Data were collected using the same questionnaire shared by 5 participating centres. A total of 2331 procedures were performed. A mean of 3593.7+/-800.3 ml of plasma or 8115.3+/-2150.1 ml of blood, depending upon the technique used (H.E.L.P., D.A.LI., Dextransulphate, Lipocollect 200), was regularly...
Source: Atherosclerosis. Supplements. - December 29, 2009 Category: Cardiology Authors: Stefanutti C, D'Alessandri G, Russi G, De Silvestro G, Zenti MG, Marson P, Belotherkovsky D, Vivenzio A, Di Giacomo S Tags: Atheroscler Suppl Source Type: journals

Effects of Pravastatin on Serum Osteoprotegerin Levels in Patients With Hypercholesterolemia and Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we examined whether treatment with pravastatin can alter osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Osteoprotegerin levels were significantly increased from 6.64 ± 2.18 pmol/L at baseline to 7.08 ± 2.29 pmol/L (P = .024) after 3-month treatment with pravastatin. These increases in osteoprotegerin levels remained after 6 months of treatment (7.05 ± 2.22 pmol/L, P = .026). These findings suggest that pravastatin may exert its pleiotropic effects in part through alteration of osteoprotegerin levels. (Source: Angiology)
Source: Angiology - December 24, 2009 Category: Cardiology Authors: Mori, K., Jono, S., Emoto, M., Kawagishi, T., Yasumoto, H., Konishi, T., Furumitsu, Y., Shioi, A., Shoji, T., Inaba, M., Nishizawa, Y. Tags: Articles Source Type: journals

Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, simultaneous treatment with statin and PKC inhibitor synergistically enhanced the antifibrotic efficacy in both in vitro and in vivo models of hepatic fibrosis and may therefore have therapeutic implication for reducing hepatic fibrosis. (Source: AJP: Gastrointestinal and Liver Physiology)
Source: AJP: Gastrointestinal and Liver Physiology - December 19, 2009 Category: Gastroenterology Authors: Yang, J. I., Yoon, J.-H., Bang, Y.-J., Lee, S.-H., Lee, S.-M., Byun, H. J., Myung, S.-J., Kim, W., Lee, H.-S. Tags: LIVER AND BILIARY TRACT Source Type: journals

Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Since pravastatin, a HMG-CoA reductase inhibitor, has recently been shown to reduce infarct volumes and glutamate release in a rat model of ischemic stroke, the aim of the present study was to investigate whether this neuroprotective effect may be due to a modulation of excitatory and inhibitory neurotransmitter receptors. Therefore, Wistar rats were treated six times in 4 days with pravastatin or saline and allowed to survive for 6 hours or 5 days (n = 10 per time point and group), respectively. Using quantitative receptor autoradiography, ligand binding densities of [(3)H]MK-801, [(3)H]AMPA, and [(3)H]muscimol for la...
Source: Brain Research - December 18, 2009 Category: Neurology Authors: Müller HD, Berger C, Schwab S, Sommer C Tags: Brain Res Source Type: journals

Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis (1)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study HDL cholesterol levels were predictive of major cardiovascular events even among patients with LDL cholesterol levels below 1.8mmol/l. (Source: Atherosclerosis)
Source: Atherosclerosis - December 18, 2009 Category: Cardiology Authors: Walter F. Riesen Tags: Invited Commentaries Source Type: journals

Rosuvastatin Better Than Pravastatin for Protease-Inhibitor-Related DyslipidemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rosuvastatin is better than pravastatin at lowering levels of LDL cholesterol and triglycerides in HIV-infected patients with protease-inhibitor (PI)-associated dyslipidemia, according to an article in the January 2nd issue of AIDS. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2009 Category: Consumer Health News Tags: HIV/AIDS Source Type: news

Rosuvastatin more effective than pravastatin in HIV-1-infected patients receiving a boosted protease inhibitorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Reuters Health News Area: News According to a randomised controlled study published in the journal AIDS, rosuvastatin 10 mg/day is more effective than pravastatin 40 mg/day at lowering levels of LDL cholesterol and triglycerides in HIV-1-infected patients receiving a boosted protease inhibitor (PI). It is well documented that HIV infection and its treatment with PIs, especially when boosted with ritonavir, can cause dyslipidaemia, and with the exception of fluvastatin, pravastatin and rosuvastatin, all statins interact with PI metabolism via CYP450. In these patients, pravastatin is recommended for pati...
Source: NeLM - Cardiovascular Medicine - December 17, 2009 Category: Cardiology Source Type: organizations

Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka–Long–Evans–Tokushima Fatty ratEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions and implications: The results suggest that long-term treatment with pravastatin improves DM and pancreatic fibrosis via anti-oxidative and anti-fibrotic properties, whereas cessation of pravastatin abolishes these beneficial effects, and accelerates DM and pancreatic fibrosis. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - December 16, 2009 Category: Drugs & Pharmacology Authors: M Otani, M Yamamoto, M Harada, M Otsuki Source Type: journals

Pravastatin: Skin ulcers and myopathy in an elderly patientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - December 15, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

PRAVASTATIN SODIUMtablet [Mylan Pharmaceuticals Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Dec 15, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - December 15, 2009 Category: Drugs & Pharmacology Source Type: organizations

Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes: From the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Although analytic techniques commonly used in clinical outcomes trials censor patients who experience a component of the primary composite end point, total cardiovascular events are important to patients, clinicians, and health care payers. Maintaining low levels of low-density lipoprotein cholesterol is central to preventing additional atherosclerotic development and subsequent cardiovascular events. Atorvastatin 80 mg, a more intensive low-density lipoprotein cholesterol lowering agent, reduced both first and subsequent primary end point events compared with pravastatin 40 mg after ACS. (Source: Journal of t...
Source: Journal of the American College of Cardiology - December 15, 2009 Category: Cardiology Authors: Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, Carolyn H. McCabe, Eugene Braunwald Tags: Lipid-Lowering and Total Cardiovascular Burden Source Type: journals

Cardiovascular Outcomes in Randomized Trials: Should Time to First Event for “Hard” End Points Remain the Standard Approach?⁎Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This issue of the Journal contains 2 papers that provide interesting insights from 2 large randomized lipid-lowering trials that addressed relatively similar scientific questions. In the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) trial, investigators compared atorvastatin (80 mg) with pravastatin (40 mg) for patients randomly assigned to treatment after an acute coronary syndrome (ACS) (). In the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial (), the 80-mg dosage of atorvastatin was compared with 20 to 40 m...
Source: Journal of the American College of Cardiology - December 15, 2009 Category: Cardiology Authors: Steven E. Nissen Tags: Lipid-Lowering and Total Cardiovascular Burden: Editorial Comment Source Type: journals

Journal Scan: Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes: From the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Trial (J Am Coll Cardiol 2009;54:2358-2362.)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This is a post-hoc analysis of the PROVE IT-TIMI 22 trial. Poisson regression analysis was performed to compare the number of occurrences of the primary endpoint between high-dose atorvastatin and pravastatin in the PROVE IT-TIMI 22 trial. (Source: Cardiosource)
Source: Cardiosource - December 12, 2009 Category: Cardiology Source Type: organizations

Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial [Patient-Oriented and Epidemiological Research]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cholesterol homeostasis, defined as the balance between absorption and synthesis, influences circulating cholesterol concentrations and subsequent coronary heart disease (CHD) risk. Statin therapy targets the rate-limiting enzyme in cholesterol biosynthesis and is efficacious in lowering CHD events and mortality. Nonetheless, CHD events still occur in some treated patients. To address differences in outcome during pravastatin therapy (40 mg/day), plasma markers of cholesterol synthesis (desmosterol, lathosterol) and fractional cholesterol absorption (campesterol, sitosterol) were measured, baseline and on treatment, in the...
Source: The Journal of Lipid Research - December 11, 2009 Category: Lipidology Authors: Matthan, N. R., Resteghini, N., Robertson, M., Ford, I., Shepherd, J., Packard, C., Buckley, B. M., Jukema, J. W., Lichtenstein, A. H., Schaefer, E. J., for the PROSPER Group Tags: Patient-Oriented and Epidemiological Research Source Type: journals

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This generally well-conducted review concluded that statin use in patients without established cardiovascular disease, but with cardiovascular risk factors, was associated with significantly improved survival and large reductions in the risk of major cardiovascular events. This conclusion reflected the results of an appropriate synthesis of large, high-quality trials and is likely to be reliable. [Included studies used pravastatin, lovastatin, atorvastatin, simvastatin or rosuvastatin.] CRD Commentary: The review question was clear and supported by spe...
Source: NeLM - Cerebrovascular Disorders - December 11, 2009 Category: Neurology Source Type: organizations

Statin response enhanced in Black CHD patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers have confirmed a significant reduction in coronary events among Black patients who received pravastatin in ALLHAT-LLT, despite the overall negative results of the study. (Source: MedWire News - Lipidology)
Source: MedWire News - Lipidology - December 10, 2009 Category: Lipidology Source Type: news

High Innate Production Capacity of Proinflammatory Cytokines Increases Risk for Death from Cancer: Results of the PROSPER Study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: High innate production capacity of proinflammatory cytokines is associated with an increased risk for death from cancer, probably because of increased tumor growth and metastasis. Because there was no association between innate production capacity and cancer incidence, the association between circulating levels and cancer incidence at least partially reflects reversed causality. (Clin Cancer Res 2009;15(24):7744-8). PMID: 19996221 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - December 8, 2009 Category: Cancer & Oncology Authors: Trompet S, de Craen AJ, Mooijaart S, Stott DJ, Ford I, Sattar N, Jukema W, Westendorp RG Tags: Clin Cancer Res Source Type: journals

Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: PCI-PROVE IT: A PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) SubstudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Among patients with ACS who undergo PCI, intensive statin therapy reduces MACE compared with moderate-dose statin therapy. The reduction in the incidence of TVR was independent of low-density lipoprotein cholesterol and C-reactive protein lowering and may therefore be due, at least in part, to a pleiotropic effect of high-dose statin therapy. (PROVE IT–TIMI 22; NCT00382460) (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - December 5, 2009 Category: Cardiology Authors: C. Michael Gibson, Yuri B. Pride, Claudia P. Hochberg, Sarah Sloan, Marc S. Sabatine, Christopher P. Cannon, TIMI Study Group Tags: Interventional Cardiology Source Type: journals

Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT-LLT)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our results suggest that pravastatin is effective in preventing CHD in blacks. (Source: American Heart Journal)
Source: American Heart Journal - December 1, 2009 Category: Cardiology Authors: Karen L. Margolis, Kay Dunn, Lara M. Simpson, Charles E. Ford, Jeff D. Williamson, David J. Gordon, Paula T. Einhorn, Jeffrey L. Probstfield, For the ALLHAT Collaborative Research Group Tags: Coronary Artery Disease Source Type: journals

Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: A simpler non-laboratory-based risk prediction model performed equally as well as the more comprehensive laboratory-based risk prediction models. The risk chart based on the further simplified Score Model may provide a useful tool for clinical cardiologists to assess an individual patient's risk for recurrent CVD events. (Source: European Journal of Cardiovascular Prevention and Rehabilitation)
Source: European Journal of Cardiovascular Prevention and Rehabilitation - December 1, 2009 Category: Cardiology Authors: Jisheng Cui, Andrew Forbes, Adrienne Kirby, John Simes, Andrew Tonkin Source Type: journals

Pravastatin: Acute pancreatitis in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 30, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients With Previous Statin IntoleranceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, red yeast rice was tolerated as well as pravastatin and achieved a comparable reduction of low-density lipoprotein cholesterol in a population previously intolerant to statins. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - November 30, 2009 Category: Cardiology Authors: Steven C. Halbert, Benjamin French, Ram Y. Gordon, John T. Farrar, Kathryn Schmitz, Patti B. Morris, Paul D. Thompson, Daniel J. Rader, David J. Becker Tags: Preventive Cardiology Source Type: journals

Apolipoprotein E Genotype, Plasma Cholesterol, and Cancer: A Mendelian Randomization StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Observational studies have shown an association between low plasma cholesterol levels and increased risk of cancer, whereas most randomized clinical trials involving cholesterol-lowering medications have not shown this association. Between 1997 and 2002, the authors assessed the association between plasma cholesterol levels and cancer risk, free from confounding and reverse causality, in a Mendelian randomization study using apolipoprotein E (ApoE) genotype. ApoE genotype, plasma cholesterol levels, and cancer incidence and mortality were measured during a 3-year follow-up period among 2,913 participants in the Prospective...
Source: American Journal of Epidemiology - November 18, 2009 Category: Epidemiology Authors: Trompet, S., Jukema, J. W., Katan, M. B., Blauw, G. J., Sattar, N., Buckley, B., Caslake, M., Ford, I., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M. Tags: RESEARCH-ARTICLE Source Type: journals

Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study is focused on utilizing human embryonic kidney (HEK) 293 cell cultures genetically transfected with the human organic anion transporting polypeptides (OATP) 1B1 transporter to identify substrates and inhibitors in drug development. The kinetics of OATP1B1-mediated uptake of [(3)H]-oestradiol 17beta-glucuronide and inhibition of uptake by rifamycin SV were used to determine K(m), V(max), and IC(50) values over a range of passage numbers to investigate accuracy and precision. The mean K(m) and V(max) values were found to be 6.3 +/- 1.2 muM and 460 +/- 96 pmol min(-1) mg(-1), respectively. The mean IC(50) value for...
Source: Xenobiotica - November 17, 2009 Category: Research Authors: Sharma P, Holmes VE, Elsby R, Lambert C, Surry D Tags: Xenobiotica Source Type: journals

Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Statins do not appear to demonstrate a ‘class effect’ on IS in patients without diabetes. Differences between individual statins likely exist that may partially explain the findings of previously conducted meta-analyses examining the impact of statins on the development of diabetes. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - November 13, 2009 Category: Endocrinology Authors: William L. Baker, Ripple Talati, C. Michael White, Craig I. Coleman Tags: Clinical Care and Education Source Type: journals

Synergistic Anti-Fibrotic Efficacy of Statin and Protein Kinase C Inhibitor in Hepatic Fibrosis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, simultaneous treatment with statin and PKC inhibitor synergistically enhanced the anti-fibrotic efficacy in both in vitro and in vivo models of hepatic fibrosis and may therefore have therapeutic implication for reducing hepatic fibrosis. PMID: 19910526 [PubMed - as supplied by publisher] (Source: Am J Physiol Gastroi...)
Source: Am J Physiol Gastroi... - November 12, 2009 Category: Gastroenterology Authors: Yang JI, Yoon JH, Bang YJ, Lee SH, Lee SM, Byun HJ, Myung SJ, Kim W, Lee HS Tags: Am J Physiol Gastrointest Liver Physiol Source Type: journals

Endothelial Function in Subjects with Isolated Low HDL Cholesterol: Role of Nitric Oxide and Circulating Progenitor Cells.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Epidemiologic studies have shown that a low level of high-density lipoprotein (HDL) cholesterol is a risk factor for cardiovascular diseases. The purpose of this study was to determine the contribution of isolated low HDL cholesterol to endothelial function. Thirty-nine subjects with low HDL cholesterol who had no other cardiovascular risk factors were selected from the 5417 participants from our population. We evaluated flow-mediated vasodilation (FMD) before and after 4 weeks of treatment with the HMG-CoA reductase inhibitor pravastatin in 29 of the 39 subjects with isolated low HDL cholesterol. FMD was lower in the ...
Source: American Journal of Physiology. Endocrinology and Metabolism - November 10, 2009 Category: Physiology Authors: Higashi Y, Maysuoka H, Umei H, Sugano R, Fujii Y, Soga J, Kihara Y, Chayama K, Imaizumi T Tags: Am J Physiol Endocrinol Metab Source Type: journals

The kif6 719arg allele is associated with increased risk of coronary heart disease among males in the welcome trust case control consortium study of coronary heart diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Carriers of the KIF6 719Arg allele, compared with noncarriers, have a higher risk of coronary heart disease (CHD) in several prospective studies and in the placebo groups of two randomized trials of pravastatin. In these trials, pravastatin treatment ameliorated the risk associated with 719Arg allele. In the Welcome Trust Case-Control Consortium (WTCCC) CHD study, although no association was observed between the 719Arg allele and CHD, a significant association between the 719Arg allele and CHD was observed in a sex-differentiated test. In order to investigate this sex-differentiated association, we analyzed the association...
Source: Atherosclerosis - November 1, 2009 Category: Cardiology Authors: D. Shiffman, C.M. Rowland, J. Thompson, A.S. Hall, J.J. Devlin, N.J. Samani Tags: BAS Autumn Meeting 2009 Abstracts Source Type: journals

Effects of increasing the dose of pravastatin on serum adiponectin level in Japanese mild hypercholesterolemic and hypertensive patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, increasing the dosage of pravastatin was investigated to determine whether it had a clearly favorable effect on the adiponectin level in hypercholesterolemic patients. A total of 26 mild hypercholesterolemic and hypertensive patients were enrolled in this study. The patients were initially treated with pravastatin 10 mg/day for 6 months or more, and then increased to pravastatin 20 mg/day. Serum adiponectin, cholesterol fractionated components, and lipoprotein components were evaluated after 6 months. Increasing the dose of pravastatin from 10 to 20 mg/day caused the low-density lipoprotein cholesterol level...
Source: Arzneimittel-Forschung - October 29, 2009 Category: Drugs & Pharmacology Authors: Kai T, Kanamasa K Tags: Arzneimittelforschung Source Type: journals

In vitro interactions between primycin and different statins in their effects against some clinically important fungi.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The in vitro antifungal activities of primycin and various statins against some opportunistic pathogenic fungi were investigated. Primycin completely inhibited the growth of Candida albicans (MIC: 64 microg ml(-1)) and Candida glabrata (MIC: 32 microg ml(-1)), and was very effective against Paecilomyces variotii (MIC: 2 microg ml(-1)), but it had little effect on Aspergillus fumigatus, Aspergillus flavus or Rhizopus oryzae (MIC: >64 microg ml(-1)). The fungi exhibited different degrees of sensitivity to the statins; fluvastatin and simvastatin exerted potent antifungal activities against a wide variety of clinically...
Source: Journal of Medical Microbiology - October 29, 2009 Category: Microbiology Authors: Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C Tags: J Med Microbiol Source Type: journals